Salix Pharmaceuticals Company Profile (NASDAQ:SLXP)

About Salix Pharmaceuticals

Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SLXP
  • CUSIP: 79543510
Key Metrics:
  • Previous Close: $169.00
  • 50 Day Moving Average: $163
  • 200 Day Moving Average: $136
  • 52-Week Range: $86.00 - $173.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.78
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Salix Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
DateFirmActionRatingPrice TargetDetails
3/18/2015Jefferies Group LLCDowngradeBuy -> Hold$149.00 -> $173.00View Rating Details
3/16/2015MizuhoBoost Price TargetNeutral$158.00 -> $173.00View Rating Details
(Data available from 3/1/2015 forward)


Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2015Q414($0.29)($2.61)$187.97 million$13.00 millionViewN/AView Earnings Details
11/6/2014Q314$1.56$1.53$394.00 million$354.70 millionViewN/AView Earnings Details
8/7/2014Q214$1.69$1.59$397.06 million$382.00 millionViewListenView Earnings Details
5/8/2014Q114$0.91$1.05$372.91 million$384.00 millionViewListenView Earnings Details
2/27/2014Q413$0.93$1.06$247.29 million$257.60 millionViewListenView Earnings Details
11/7/2013Q313$0.86$0.89$239.70 million$238.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.81$0.87$226.34 million$235.40 millionViewListenView Earnings Details
5/9/2013Q1 2013$0.67$0.63$205.94 million$202.60 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.78$0.81$199.41 million$198.17 millionViewN/AView Earnings Details
11/7/2012Q312$0.69$0.95$187.23 million$185.13 millionViewN/AView Earnings Details
8/8/2012$0.54$0.79ViewN/AView Earnings Details
5/7/2012$0.56$0.67ViewN/AView Earnings Details
11/8/2011$0.60$0.77ViewN/AView Earnings Details
8/8/2011$0.44$0.32ViewN/AView Earnings Details
5/5/2011$0.17$0.34ViewN/AView Earnings Details
2/28/2011$0.49$0.66ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS


Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Salix Pharmaceuticals (NASDAQ:SLXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2015Timothy J CreechInsiderSell4,600$157.67$725,282.00View SEC Filing  
3/6/2015William P ForbesEVPSell20,000$157.96$3,159,200.00View SEC Filing  
11/12/2014William P ForbesEVPSell11,079$95.05$1,053,058.95View SEC Filing  
6/26/2014Carolyn J LoganCEOSell53,057$123.38$6,546,172.66View SEC Filing  
4/22/2014Alonzo Thomas DDirectorSell11,530$110.89$1,278,561.70View SEC Filing  
1/10/2014Alonzo Thomas DDirectorSell12,050$91.83$1,106,551.50View SEC Filing  
1/9/2014Adam DerbyshireCFOSell30,001$91.48$2,744,491.48View SEC Filing  
1/8/2014William ForbesEVPSell8,000$90.06$720,480.00View SEC Filing  
1/7/2014Rick ScruggsEVPSell8,463$88.31$747,367.53View SEC Filing  
1/7/2014William KeaneDirectorSell22,500$88.31$1,986,975.00View SEC Filing  
7/24/2013William P ForbesEVPSell12,000$70.93$851,160.00View SEC Filing  
4/10/2013William P ForbesEVPSell8,673$49.37$428,186.01View SEC Filing  
12/26/2012Adam C DerbyshireCFOSell60,000$41.44$2,486,400.00View SEC Filing  
11/13/2012Mark A SirgoDirectorSell3,450$40.53$139,828.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
DateHeadline logo[$$] Allergan Admits to Disclosure Violations During Valeant Bid (NASDAQ:SLXP) - February 9 at 4:24 AM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Under Analyst Spotlight - UK Market News (NASDAQ:SLXP) - January 29 at 8:58 PM logoValeant將向歐萊雅出售三個護膚品牌 - 華爾街日報 (NASDAQ:SLXP) - January 10 at 11:11 PM logoValeant将向欧莱雅出售三个护肤品牌 - 华尔街日报中文网 (NASDAQ:SLXP) - January 10 at 11:11 PM logoValeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says (NASDAQ:SLXP) - December 16 at 3:56 AM
News IconValeant Inc: Valeant Stock Drops After Baffling Move - Lombardi Letter (NASDAQ:SLXP) - December 2 at 7:29 PM logoValeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda ... - Insider Monkey (blog) (NASDAQ:SLXP) - December 2 at 7:29 PM logoHow Does Valeant Plan to Resume Growth beyond 2016? (NASDAQ:SLXP) - December 1 at 7:45 PM
News IconValeant: How this $10 Billion Deal Killed VRX Stock Today (NASDAQ:SLXP) - December 1 at 1:11 AM logoWhy Valeant is Crumbling (NASDAQ:SLXP) - December 1 at 1:11 AM
News IconValeant: How this $10 Billion Deal Killed VRX Stock Today - Profit Confidential (NASDAQ:SLXP) - November 30 at 8:09 PM logoValeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?! (NASDAQ:SLXP) - November 30 at 8:09 PM logoValeant, Salix, Sales Force and Asset Sales (NASDAQ:SLXP) - November 30 at 8:09 PM logoUh Oh, Valeant's Hiring. Why That's Very Bad News. (NASDAQ:SLXP) - November 30 at 10:42 AM logoValeant's Asset Sale Clock is Ticking (NASDAQ:SLXP) - November 21 at 12:47 PM logoIs Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime? (NASDAQ:SLXP) - November 18 at 7:07 PM
News IconSalix Pharmaceuticals Ltd. SLXP Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SLXP) - November 18 at 10:49 AM logoBranded Rx Still a Pain for Valeant Pharmaceuticals (NASDAQ:SLXP) - November 14 at 11:45 AM logo[$$] New Valeant chief nurses $1.3m paper loss on shares (NASDAQ:SLXP) - November 13 at 11:23 AM logoAckman: Valeant Can Sell Non-Core Assets to Reduce Debt (NASDAQ:SLXP) - November 10 at 7:29 PM logoValeant’s 3Q16 Earnings: What Will Drive Its Revenue? (NASDAQ:SLXP) - November 10 at 10:51 AM logoSelling Salix Could Be the Most "Valeant" Move Ever (NASDAQ:SLXP) - November 9 at 7:34 PM logoValeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 Report (NASDAQ:SLXP) - November 9 at 10:15 AM
News IconValeant Pharmaceuticals Intl Inc: VRX Stock Is Getting Crushed … Again - Profit Confidential (NASDAQ:SLXP) - November 8 at 7:24 PM logoValeant's Possible Fire Sale Looks Worse Than Ever (NASDAQ:SLXP) - November 8 at 7:24 PM logoValeant adj profit misses estimates; FY forecast cut (NASDAQ:SLXP) - November 8 at 11:22 AM logoHow Valeant’s Salix Sales News Could Be Positive for Investors (NASDAQ:SLXP) - November 8 at 11:22 AM logo[$$] Valeant shares fall after sales and earnings targets cut (NASDAQ:SLXP) - November 8 at 11:22 AM logoAnalysts Remain Wary Ahead of Valeant Earnings (NASDAQ:SLXP) - November 7 at 8:23 PM logoValeant earnings: Expect an update on plans to sell Salix (NASDAQ:SLXP) - November 7 at 8:23 PM logoValeant to Sell Salix Business to Takeda (NASDAQ:SLXP) - November 3 at 7:32 PM logo[$$] Valeant: I love you, you pay my rent (NASDAQ:SLXP) - November 2 at 7:51 PM logoNegative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11% (NASDAQ:SLXP) - November 2 at 7:51 PM logoValeant: A Good Strategic Move? (NASDAQ:SLXP) - November 2 at 7:51 PM logoValeant: Selling Salix a Warning of Trouble to Come? (NASDAQ:SLXP) - November 2 at 11:02 AM logoHold the Valeant Applause (NASDAQ:SLXP) - November 2 at 11:02 AM logoValeant’s Investment Here Could Improve Future Profit Margins (NASDAQ:SLXP) - October 18 at 12:43 PM
News IconControversy Over Lead Poisoning Drug Pricing - PharmaLive (press release) (subscription) (NASDAQ:SLXP) - October 12 at 7:17 PM
News IconBroker Changes For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - NewsDen (NASDAQ:SLXP) - October 11 at 1:29 PM
News IconValeant Pharmaceuticals Intl Inc: VRX Stock to Regain Value? - Profit Confidential (NASDAQ:SLXP) - September 27 at 7:15 PM logoValeant’s Strategies for Its Dermatology, Gastroenterology Drugs (NASDAQ:SLXP) - September 20 at 12:07 PM
News IconValeant Stock: Many Are Bullish on Valeant Pharmaceuticals Intl Inc - Profit Confidential (NASDAQ:SLXP) - September 19 at 11:55 AM logoValeant: Are the Salix and Dermatology Portfolios Recovering? (NASDAQ:SLXP) - September 14 at 11:43 AM logoValeant gets new approval for legacy Salix drug (NASDAQ:SLXP) - July 20 at 1:50 PM logoValeant's Drug Approvals May Save the Day (NASDAQ:SLXP) - July 20 at 12:30 PM logoValeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles (NASDAQ:SLXP) - July 20 at 9:21 AM logoHow Much Is Valeant Pharmaceuticals Really Worth? (NASDAQ:SLXP) - June 17 at 2:41 PM
News IconPfizer Drug Prices Rise By 8.8% Average - PharmaLive (press release) (subscription) (NASDAQ:SLXP) - June 11 at 10:25 AM logoDoctors Who Prescribed Salix Drugs Ate Well (NASDAQ:SLXP) - June 10 at 3:43 PM logoDetails of kickbacks and fraud emerge in Valeant's Salix unit settlement (NASDAQ:SLXP) - June 10 at 11:55 AM


What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

How do I buy Salix Pharmaceuticals stock?

Shares of Salix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Salix Pharmaceuticals stock cost?

One share of Salix Pharmaceuticals stock can currently be purchased for approximately $169.00.

Salix Pharmaceuticals (NASDAQ:SLXP) Chart for Wednesday, March, 1, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)

Earnings History Chart

Earnings by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)

Dividend History Chart

Dividend Payments by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)

Last Updated on 3/1/2017 by Staff